Drug Trial Radar · NCT01968031
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
613
Actual
Start
Oct 2013
Primary completion
Oct 2016
Study completion Oct 2016
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Hakko Kirin Pharma, Inc.
- First posted
- Oct 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to assess the efficacy and safety of oral Istradefylline (KW-6002) in patients with moderate to severe Parkinson's Disease. While on this study, participants will continue to take their usual, prescribed, stable regimen of Levodopa/Carbidopa or Levodopa/Benserazide therapy plus adjunct Parkinson's medications. Patients will be randomized 1:1:1 to receive either Istradefylline 20 mg per day, or Istradefylline 40 mg per day or an equivalent placebo. Patients will be treated for a 12 week period to demonstrate the effectiveness of Istradefylline in improving Parkinson's disease symptoms (referred to as improvement in patient OFF time) and that Istradefylline has an acceptable safety profile in this group.
Conditions
- Idiopathic Parkinson's Disease
Interventions
Istradefylline 40 mgDrug
Istradefylline 40 mg and placebo
Istradefylline 20 mgDrug
Istradefylline 20 mg and placebo
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Total Hours of Awake Time/Day Spent in the OFF State at Week 12Time frame: Baseline, Week 2, Week 6, Week 10 and Week 12.
Locations
89 sites in 8 countries. Site status is shown where the registry gives one.
Kyowa PD Site
Phoenix, Arizona
Kyowa PD Site
Sun City, Arizona
Kyowa PD Site
Tucson, Arizona
Kyowa PD Site
Fountain Valley, California
Kyowa PD Site
Irvine, California
Kyowa PD Site
Los Angeles, California
Kyowa PD Site
Oxnard, California
Kyowa PD Site
Pasadena, California
Kyowa PD Site
Reseda, California
Kyowa PD Site
Sunnyvale, California
Kyowa PD Site
Torrance, California
Kyowa PD Site
Englewood, Colorado
Kyowa PD Site
Danbury, Connecticut
Kyowa PD Site
Boca Raton, Florida
Kyowa PD Site
Jacksonville, Florida
Kyowa PD Site
Panama City, Florida
Kyowa PD Site
Port Charlotte, Florida
Kyowa PD Site
Tampa, Florida
Kyowa PD Site
Atlanta, Georgia
Kyowa PD Site
Augusta, Georgia
Kyowa PD Site
Chicago, Illinois
Kyowa PD Site
Chicago, Illinois
Kyowa PD Site
Des Moines, Iowa
Kyowa PD Site
Kansas City, Kansas
Kyowa PD Site
Baltimore, Maryland
Kyowa PD Site
Boston, Massachusetts
Kyowa PD Site
West Bloomfield, Michigan
Kyowa PD Site
Minneapolis, Minnesota
Kyowa PD Site
St Louis, Missouri
Kyowa PD Site
Albany, New York
Kyowa PD Site
New York, New York
Kyowa PD Site
New York, New York
Kyowa PD Site
Asheville, North Carolina
Kyowa PD Site
Durham, North Carolina
Kyowa PD Site
Cincinnati, Ohio
Kyowa PD Site
Cleveland, Ohio
Kyowa PD Site
Toledo, Ohio
Kyowa PD Site
Philadelphia, Pennsylvania
Kyowa PD Site
Charleston, South Carolina
Kyowa PD Site
Dallas, Texas
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.